B+
Bull case
20%
Probability
Target price
$19.00
Analysis reference price unavailable
Analysis 2026-09-03 · RankAlpha Sentiment Codex
QDEL
QuidelOrthoANasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$15.00
Analysis reference price unavailable
Analysis 2026-09-03 · RankAlpha Sentiment Codex
B-
Bear case
35%
Probability
Target price
$10.00
Analysis reference price unavailable
Analysis 2026-09-03 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-03
Recent news sentiment (30D)
-0.6
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+87.3
Score
AI commentary
Recent coverage is mixed-to-negative: Q2 exceeded stored revenue and adjusted-EPS estimates, but the company cut guidance and withdrew free-cash-flow guidance, followed by a negative market reaction. Social, options, short-interest, and employee-sentiment data are unavailable; low coverage limits confidence.
RankAlpha Sentiment Codex - 2026-09-03
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-09-30catalystChina and respiratory weakness remain downside triggersHigh impact
Management attributed pressure to China IVD pricing uncertainty and a softer global respiratory environment; full-year revenue and earnings guidance were reduced and free-cash-flow guidance withdrawn [#SEC-8K-2026-08-06].
2026-11-05eventPost-Q2 execution checkpointHigh impact
Q2 revenue grew 3% reported, adjusted EBITDA margin improved to 20.5%, and Point of Care revenue grew 16%, but investors must assess whether ex-China growth and cost actions can offset respiratory and China weakness [#SEC-8K-2026-08-06].
2027-09-03catalystPortfolio execution and deleveragingHigh impact
Longer-term upside depends on sustained core-franchise growth, respiratory-season execution, working-capital improvement, and leverage reduction; the evidence remains early and unproven.
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-03 • Updated nightlySource: Internal modelMethodology